Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1896 1
1898 1
1947 1
1951 1
1953 1
1958 3
1960 2
1961 1
1963 1
1971 1
1974 1
1976 2
1977 3
1978 3
1979 2
1980 7
1981 10
1982 6
1983 15
1984 18
1985 15
1986 19
1987 17
1988 14
1989 20
1990 16
1991 12
1992 13
1993 14
1994 12
1995 17
1996 27
1997 22
1998 15
1999 20
2000 23
2001 21
2002 30
2003 27
2004 39
2005 72
2006 93
2007 114
2008 78
2009 33
2010 16
2011 16
2012 12
2013 5
2014 8
2015 12
2016 6
2017 4
2018 7
2019 5
2020 10
2021 5
2022 5
2024 0

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 18381948

904 results

Results by year

Filters applied: . Clear all
Page 1
Anemia is a significant prognostic factor in local relapse-free survival of premenopausal primary breast cancer patients receiving adjuvant cyclophosphamide/methotrexate/5-fluorouracil chemotherapy.
Dubsky P, Sevelda P, Jakesz R, Hausmaninger H, Samonigg H, Seifert M, Denison U, Mlineritsch B, Steger G, Kwasny W, Stöger H, Bartsch R, Stierer M, Taucher S, Fridrik M, Schippinger W, Greil R, Pötter R, Gnant M; Austrian Breast and Colorectal Cancer Study Group. Dubsky P, et al. Clin Cancer Res. 2008 Apr 1;14(7):2082-7. doi: 10.1158/1078-0432.CCR-07-2068. Clin Cancer Res. 2008. PMID: 18381948 Clinical Trial.
Conventional adjuvant chemotherapy versus single-cycle, autograft-supported, high-dose, late-intensification chemotherapy in high-risk breast cancer patients: a randomized trial.
Leonard RC, Lind M, Twelves C, Coleman R, van Belle S, Wilson C, Ledermann J, Kennedy I, Barrett-Lee P, Perren T, Verrill M, Cameron D, Foster E, Yellowlees A, Crown J; Anglo-Celtic Cooperative Oncology Group. Leonard RC, et al. J Natl Cancer Inst. 2004 Jul 21;96(14):1076-83. doi: 10.1093/jnci/djh188. J Natl Cancer Inst. 2004. PMID: 15265969 Clinical Trial.
Randomized trial comparing cyclophosphamide, epirubicin, and fluorouracil with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer: update of National Cancer Institute of Canada Clinical Trials Group Trial MA5.
Levine MN, Pritchard KI, Bramwell VH, Shepherd LE, Tu D, Paul N; National Cancer Institute of Canada Clinical Trials Group. Levine MN, et al. J Clin Oncol. 2005 Aug 1;23(22):5166-70. doi: 10.1200/JCO.2005.09.423. J Clin Oncol. 2005. PMID: 16051958 Clinical Trial.
Oral uracil and tegafur compared with classic cyclophosphamide, methotrexate, fluorouracil as postoperative chemotherapy in patients with node-negative, high-risk breast cancer: National Surgical Adjuvant Study for Breast Cancer 01 Trial.
Watanabe T, Sano M, Takashima S, Kitaya T, Tokuda Y, Yoshimoto M, Kohno N, Nakagami K, Iwata H, Shimozuma K, Sonoo H, Tsuda H, Sakamoto G, Ohashi Y. Watanabe T, et al. J Clin Oncol. 2009 Mar 20;27(9):1368-74. doi: 10.1200/JCO.2008.18.3939. Epub 2009 Feb 9. J Clin Oncol. 2009. PMID: 19204202 Clinical Trial.
Similar efficacy for ovarian ablation compared with cyclophosphamide, methotrexate, and fluorouracil: from a randomized comparison of premenopausal patients with node-positive, hormone receptor-positive breast cancer.
Ejlertsen B, Mouridsen HT, Jensen MB, Bengtsson NO, Bergh J, Cold S, Edlund P, Ewertz M, de Graaf PW, Kamby C, Nielsen DL. Ejlertsen B, et al. J Clin Oncol. 2006 Nov 1;24(31):4956-62. doi: 10.1200/JCO.2005.05.1235. J Clin Oncol. 2006. PMID: 17075113 Clinical Trial.
904 results